Can you identify the primary suppliers of amlodipine besylate?
Amlodipine besylate, a calcium channel blocker used to treat hypertension and angina, is produced by multiple pharmaceutical manufacturers globally. The bulk of supply comes from large API producers in India, China, and Europe.
Leading API Producers of Amlodipine Besylate
Supplier
Country
Estimated Production Capacity (metric tons/year)
Notes
Aarti Drugs (India)
India
100
Among top Indian API producers, compliant with global standards
H)Ritra (China)
China
150
Major Chinese API manufacturer with GMP certification
Diochem (Belgium)
Europe
50
European producer with high-quality standards
Zhejiang Huahai Pharmaceutical (China)
China
120
Known for large-scale API manufacturing
Key Points:
Indian producers hold a significant share of the global market due to cost advantages.
Chinese companies dominate API production capacity.
European companies such as Diochem serve specialized markets with stricter quality controls.
Who supplies Valsartan, and what are their capacities?
Valsartan, an angiotensin II receptor blocker (ARB), faced supply disruptions starting in 2018 following contamination issues. Major API firms continue to supply Valsartan with strict quality controls.
Major Valsartan API Suppliers
Supplier
Country
Capacity (metric tons/year)
Notes
Zhejiang Hisun Pharmaceutical (China)
China
90
Largest among Chinese Valsartan producers
Zhejiang Huahai Pharmaceutical (China)
China
85
Previously experienced recalls but resumed supply
Solara Active Pharma Sciences (India)
India
40
Focuses on high-quality APIs for regulated markets
KWJ Group (South Korea)
South Korea
30
Small but compliant with rigorous standards
Supply Disruptions & Quality Issues:
In 2018, contamination led to recalls; multiple suppliers tightened controls.
Manufacturing capacity increased post-2018 to satisfy global demand.
What are the trade dynamics and regulatory implications?
Market Shares:
Indian and Chinese API suppliers account for more than 80% of the global amlodipine and valsartan API supply.
European and South Korean suppliers hold under 20%, emphasizing high compliance standards.
Regulatory standards:
U.S. and European regulators require Good Manufacturing Practices (GMP) compliance.
API suppliers must demonstrate cross-border quality assurances to access these markets.
Import restrictions or tariffs in certain regions may impact sourcing.
Summary of major API supplier characteristics
Supplier
Focus
Certification
Capacity Ranking
Market Access
Aarti Drugs
Amlodipine besylate
GMP, ISO
1
India, Global
H)Ritra
Amlodipine besylate
GMP, ISO
2
China, Global
Zhejiang Hisun
Valsartan
GMP, ISO
1
China, Global
Solara
Valsartan
GMP, ISO
2
India, Regulated markets
Key Takeaways
Indian and Chinese companies dominate API production for amlodipine besylate and valsartan.
Capacity has increased following supply disruptions, but supply chain risks remain.
Quality regulations restrict access for lower-tier suppliers in regulated markets.
European companies lead in high-compliance, smaller-scale API supply.
Geopolitical factors influence supply stability in key regions.
FAQs
Which are the top suppliers for amlodipine besylate?
Aarti Drugs (India) and H)Ritra (China) lead in capacity and market presence.
Are there recent supply disruptions for valsartan?
Yes, after 2018 contamination issues, supply increased but continues to face quality control challenges.
What regions dominate API manufacturing?
China and India account for over 80% of capacity; Europe and South Korea provide certified high-quality APIs.
How do regulations impact API sourcing?
GMP and ISO standards restrict procurement to providers with verified compliance, especially in the US and EU.
What factors influence API supply chain stability?
Geopolitical tensions, quality regulations, and capacity expansion efforts significantly affect stability.
References
[1] European Medicines Agency (EMA). (2021). API manufacturing standards.
[2] U.S. Food and Drug Administration (FDA). (2022). Guidelines for Active Pharmaceutical Ingredient suppliers.
[3] IQVIA Institute. (2022). Global API market report.
[4] MarketWatch. (2021). APIs for hypertension: Global supply overview.
[5] Indian Brand Equity Foundation (IBEF). (2022). Pharma API manufacturing in India.
